腺苷5'-单磷酸通过激活AMPK并抑制IL-1β炎性细胞因子预防脓毒症相关肌肉消耗
该研究在小鼠盲肠结扎穿孔脓毒症模型中腹腔注射AMP(0.5 mg/g)或生理盐水对照,并在C2C12肌母细胞和RAW264.7巨噬细胞中进行体外实验,同时分析脓毒症患者血浆样本。结果显示AMP抑制脓毒症诱导的炎性细胞因子产生,通过减弱mTORC1激活和调节AMPK信号改善肌力、保留肌肉质量并减少全身炎症。体外AMP抑制LPS诱导的RAW264.7巨噬细胞IL-1β产生,减轻LPS或IL-1β诱导的C2C12肌管萎缩并促细胞向快肌表型转变。临床样本显示伴肌肉消耗的脓毒症患者炎性细胞因子升高。结论提示AMP通过激活AMPK和抑制IL-1β介导通路减轻脓毒症相关肌肉消耗,可能成为保留脓毒症骨骼肌功能与形态的新治疗剂。
要点
- 小鼠CLP脓毒症模型中腹腔注射AMP 0.5 mg/g可改善前肢握力并保留肌肉质量,同时减少全身炎症。
- AMP的体外效应:抑制LPS诱导的RAW264.7巨噬细胞IL-1β产生,减轻LPS或IL-1β诱导的C2C12肌管萎缩。
- 机制上AMP通过减弱mTORC1激活和调节AMPK信号通路发挥作用,并促使肌管细胞向快肌表型转变。
- 临床脓毒症伴肌肉消耗患者血浆炎性细胞因子升高,支持IL-1β相关通路在SAMW中的转化相关性。
- 目前证据仅来自小鼠模型和体外细胞实验,AMP用于脓毒症患者预防肌肉消耗的疗效与安全性尚未在临床研究中验证。
适用人群与场景
- 体内实验:雄性C57BL/6小鼠盲肠结扎穿孔脓毒症模型。
- 体外实验:C2C12肌母细胞和RAW264.7巨噬细胞。
- 临床样本分析:脓毒症患者血浆样本(具体纳入排除标准原文未提及)。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 小鼠脓毒症模型建立后腹腔注射AMP 0.5 mg/g或生理盐水对照(具体给药频次和疗程原文未提及)。
- 体外C2C12肌母细胞和RAW264.7巨噬细胞在标准条件下培养并给予AMP处理(具体浓度和给药方案原文未提及)。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:动物实验(小鼠CLP脓毒症模型)联合体外细胞实验及临床血浆样本分析;样本量、中心数原文未提及。
- 体内:AMP(0.5 mg/g腹腔注射)抑制脓毒症诱导的炎性细胞因子产生,改善前肢握力,保留肌肉质量并减少全身炎症。
- 体外:AMP抑制LPS诱导的RAW264.7巨噬细胞IL-1β产生,减轻LPS或IL-1β诱导的C2C12肌管萎缩,促使细胞向快肌表型转变。
- 机制:AMP减弱mTORC1激活并调节AMPK信号通路。
- 临床样本:伴肌肉消耗的脓毒症患者炎性细胞因子升高。
证据类型、等级与局限
- 证据类型:基础研究(动物实验+体外细胞实验)及临床样本分析,非RCT或临床干预研究。
- 证据等级或推荐强度原文未提及。
- 局限:AMP疗效仅在 mouse CLP脓毒症模型和细胞实验中验证,临床样本仅为血浆炎性细胞因子分析,未在脓毒症患者中验证AMP治疗SAMW的疗效与安全性;样本量、给药频次和疗程等细节原文未提及。
对床旁实践的改变
- 该内容不改变当前急诊/ICU对脓毒症相关肌肉消耗的临床实践:AMP(0.5 mg/g腹腔注射)的疗效仅在小鼠脓毒症模型中验证,尚未在脓毒症患者中确立治疗推荐。
- 适用人群:仅限基础研究层面;临床脓毒症伴肌肉消耗患者血浆炎性细胞因子升高,但AMP用于此类患者的获益与风险未知。
- 常见陷阱:不可将小鼠腹腔注射AMP 0.5 mg/g的剂量外推至临床患者;AMP的给药频次、疗程及人体安全剂量原文未提及。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis-associated muscle wasting (SAMW) causes long-term functional decline, even after recovery. Emerging evidence indicates that adenosine 5'-monophosphate (AMP) confers organ-protective effects in response to physiological stress or injury, potentially through the activation of AMP-activated protein kinase (AMPK) signalling pathways. In this study, we investigated the effects of AMP on SAMW to evaluate its efficacy as a therapeutic agent to alleviate SAMW.
METHODS: In vivo, a mouse model of cecum ligation and puncture sepsis was established using male C57BL/6 mice, which received intraperitoneal AMP (0.5 mg/g) or saline as a control. In vitro, C2C12 myoblasts and RAW264.7 macrophages were cultured under standard conditions and treated with AMP. Forelimb grip strength, blood and muscle sampling, western blotting, AMP assays, RNA sequencing, ELISA, flow cytometry, real-time PCR, immunohistochemistry, histology, and computed tomography imaging were performed to assess molecular, cellular, and physiological responses. In addition, plasma samples from patients with sepsis were analysed to explore translational relevance.
RESULTS: AMP suppressed sepsis-induced inflammatory cytokine production and improved muscle strength by attenuating mammalian target of rapamycin complex 1 activation and modulating AMPK signaling, thereby contributing to the preservation of muscle mass and a reduction in systemic inflammation. In vitro, AMP suppressed LPS- induced IL-1β production in RAW264.7 macrophages and attenuated LPS- or IL-1β-induced myotube atrophy in C2C12 cells and shifted the cells towards a fast-twitch phenotype. Evaluation of clinical samples revealed elevated inflammatory cytokines in patients with sepsis exhibiting muscle wasting.
CONCLUSIONS: This study demonstrates that AMP effectively mitigates SAMW by activating AMPK and suppressing IL-1β-mediated molecular pathways. These findings highlight the potential of AMP as a novel therapeutic agent for preserving skeletal muscle functionality and morphology in sepsis.
参考来源
- Yoshihara I, Yoshihara N, Hanafusa K, et al. Adenosine 5'-monophosphate prevents sepsis-associated muscle wasting by activating AMPK and suppressing IL-1β inflammatory cytokines. J Intensive Care. 2026. PMID: 42401936. doi:10.1186/s40560-026-00901-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。